Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Gay

Showing results (61-70 of 174) with videos related to

Pageof 18
Sort By:
Cancers|July 29, 2025
The Emerging Role of Left Atrial Strain in Cardiovascular Risk Stratification for Multiple Myeloma Patients Undergoing Carfilzomib TherapyAnna Colomba, Lorenzo Airale, Alice Lasagno, et al.
Cancers|July 29, 2025
Validation of the HFA-ICOS Score for Carfilzomib-Induced Cardiotoxicity in Multiple Myeloma: A Real-Life Perspective StudyAnna Astarita, Giulia Mingrone, Lorenzo Airale, et al.
Cancers|September 14, 2024
Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk AssessmentAnna Colomba, Anna Astarita, Giulia Mingrone, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 18, 2015
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)Cristina Nanni, Elena Zamagni, Annibale Versari, et al.
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 23, 2017
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)Cristina Nanni, Annibale Versari, Stephane Chauvie, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myelomaAntonio Palumbo, Ilaria Avonto, Benedetto Bruno, et al.
Cancer|October 20, 2011
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myelomaShaji K Kumar, Martha Q Lacy, Angela Dispenzieri, et al.
Hemasphere|September 4, 2023
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi StudyKarthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, et al.
Pharmacoeconomics|October 29, 2025
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry DataAdam Irving, Dennis Petrie, Anthony Harris, et al.
Pageof 18

Showing results (61-70 of 174) with videos related to

Sort By:
Pageof 18
Cancers|July 29, 2025
The Emerging Role of Left Atrial Strain in Cardiovascular Risk Stratification for Multiple Myeloma Patients Undergoing Carfilzomib TherapyAnna Colomba, Lorenzo Airale, Alice Lasagno, et al.
Cancers|July 29, 2025
Validation of the HFA-ICOS Score for Carfilzomib-Induced Cardiotoxicity in Multiple Myeloma: A Real-Life Perspective StudyAnna Astarita, Giulia Mingrone, Lorenzo Airale, et al.
Cancers|September 14, 2024
Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk AssessmentAnna Colomba, Anna Astarita, Giulia Mingrone, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 18, 2015
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)Cristina Nanni, Elena Zamagni, Annibale Versari, et al.
Blood Cancer Journal|August 1, 2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panelNoopur Raje, Kenneth Anderson, Hermann Einsele, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 23, 2017
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)Cristina Nanni, Annibale Versari, Stephane Chauvie, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myelomaAntonio Palumbo, Ilaria Avonto, Benedetto Bruno, et al.
Cancer|October 20, 2011
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myelomaShaji K Kumar, Martha Q Lacy, Angela Dispenzieri, et al.
Hemasphere|September 4, 2023
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi StudyKarthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, et al.
Pharmacoeconomics|October 29, 2025
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry DataAdam Irving, Dennis Petrie, Anthony Harris, et al.
Pageof 18